FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach

Weiqiang Lü(East China University of Science and Technology), Feixiong Cheng(East China University of Science and Technology), Jing Jiang(East China University of Science and Technology), Chen Zhang(East China University of Science and Technology), Xiaokang Deng(East China University of Science and Technology), Zhongyu Xu(East China University of Science and Technology), Shien Zou(Obstetrics and Gynecology Hospital of Fudan University), Xu Shen(Shanghai Institute of Materia Medica), Yun Tang(East China University of Science and Technology), Jin Huang(East China University of Science and Technology)
Scientific Reports
January 29, 2015
Cited by 46Open Access
Full Text

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are worldwide used drugs for analgesic, antipyretic, and anti-inflammatory therapeutics. However, NSAIDs often cause several serious liver injuries, such as drug-induced liver injury (DILI), and the molecular mechanisms of DILI have not been clearly elucidated. In this study, we developed a systems pharmacology approach to explore the mechanism-of-action of NSAIDs. We found that the Farnesoid X Receptor (FXR) antagonism of NSAIDs is a potential molecular mechanism of DILI through systematic network analysis and in vitro assays. Specially, the quantitative real-time PCR assay reveals that indomethacin and ibuprofen regulate FXR downstream target gene expression in HepG2 cells. Furthermore, the western blot shows that FXR antagonism by indomethacin induces the phosphorylation of STAT3 (signal transducer and activator of transcription 3), promotes the activation of caspase9, and finally causes DILI. In summary, our systems pharmacology approach provided novel insights into molecular mechanisms of DILI for NSAIDs, which may propel the ways toward the design of novel anti-inflammatory pharmacotherapeutics.


Related Papers